New Alzheimer’s Drug Trial Results

A New Clinical Trial Tests Acupuncture’s Impact on Tinnitus and Brain Function

A research team is preparing to launch a clinical trial that will investigate acupuncture as a treatment for chronic tinnitus. The study, which has not yet begun recruiting participants, will enroll 72 adults. It aims not only to measure changes in tinnitus symptoms but also to connect those changes to specific, measurable shifts in how the auditory brainstem processes sound signals.

How the Clinical Trial is Designed

The trial protocol is a matched case-control and self-controlled study. It will first compare two groups: adults aged 18-60 with chronic tinnitus, and a control group of healthy individuals matched for age and sex. This initial comparison will use Auditory Brainstem Response (ABR) testing to characterize specific abnormalities in the auditory conduction pathway associated with tinnitus.

The intervention involves a course of 10 acupuncture sessions for the tinnitus patient group. The study will then analyze changes within this group from before treatment to after treatment. Researchers will collect two types of data: clinical outcomes from patient-reported questionnaires, and biological data from the ABR tests.

The primary clinical measures are the Tinnitus Handicap Inventory (THI) and the Tinnitus Effects Questionnaire (TEQ). Key ABR parameters include the amplitude of wave I and the latency of wave V, which are indicators of neural signal strength and transmission speed in the early auditory pathway.

The Scientific Rationale Behind the Study

While acupuncture has been used for tinnitus management, evidence for its efficacy has often been mixed, and a clear neurophysiological mechanism has been elusive. The ABR test provides an objective, non-invasive method to assess the function of the auditory nerve and brainstem structures. Changes in ABR wave patterns have been observed in some individuals with tinnitus, suggesting a potential disruption in neural signaling.

This trial seeks to directly link a subjective experience—the perception and distress of tinnitus—to an objective biological measurement. If acupuncture leads to both a reduction in THI/TEQ scores and a normalization of ABR parameters, it would provide stronger evidence for the treatment’s effect on the underlying auditory pathology, not just the symptom.

Who Can Participate and Current Status

Eligibility criteria are specific. Participants must be between 18 and 60 years old, with no history of chronic disease, head injury, or family genetic psychiatric/neurological disease. Exclusion criteria include pregnancy or breastfeeding, metallic implants that contraindicate ABR testing, and current participation in another interventional trial.

As of now, the trial status is NOT_YET_RECRUITING. The enrollment target is 72 total participants. The study is classified as an interventional trial but does not have a designated Phase (NA), which is common for investigator-initiated studies exploring mechanisms.

Potential Implications for Patients and Hearing Research

The outcomes of this trial could impact tinnitus treatment in two main ways. First, it may generate more robust data on the clinical efficacy of a specific acupuncture protocol. Second, and more significantly, it could identify ABR markers that correlate with successful treatment. Such biomarkers would be a valuable tool for the field, allowing future researchers and clinicians to assess treatment effects objectively and potentially tailor therapies to individual neurophysiological profiles.

For patients, a successful trial could validate a non-pharmacological, low-risk treatment option. It could also advance the understanding of tinnitus from a purely subjective condition to one with identifiable biological correlates, which may help in diagnosis and monitoring progress.

This article is for informational purposes only. Consult a qualified professional for personalised advice.

Source:
Efficacy of Acupuncture on Chronic Tinnitus and Its Association With Auditory Brainstem Response Measures (ClinicalTrials.gov: NCT07522567)